Somatocrinin (growth hormone releasing factor) in vitro bioactivity; Ca++ involvement, cAMP mediated action and additivity of effect with PGE2

The release of GH induced by purified hypothalamic GRF or native or synthetic tumor-derived GRF is antagonized by the presence of CoCl²; it is simulated by 8Br .cAMP, IBMX, cholera toxin, forskolin, with identical maximal effects (E_max). Somatocrinin (GRF) stimulates the efflux of cAMP by the pituitary cells in parallel to the release of GH. Addition of either 8Br .cAMP, IBMX, cholera toxin or forskolin to a maximally stimulating dose of GRF does not increase the response which remains GRF-E_max. In contradistinction with these results PGE₂ releases GH with a dose-response curve different from that of GRF, and the combination of PGE₂ + GRF produces an E_max far greater than that due to either agonist alone; showing a true additivity. The name $\text{somatocrinin}$ is proposed to replace the acronym GRF.